Trastuzumab in combination with AT-101 induces cytotoxicity and apoptosis in Her2 positive breast cancer cells

AT-101 is a polyphenolic compound with potent anti-apoptotic effects in various cancers. In this study, the possible synergistic cytotoxic and apoptotic effect of trastuzumab/AT-101 combination was investigated in HER2-positive breast cancer cell lines. SKBR-3, MDA-MB-453 and MCF-10A cell lines were...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2020-01, Vol.16 (3), p.4485-4495
Main Authors: Bulut, Gulcan, Atmaca, Harika, Karaca, Burcak
Format: Article
Language:English
Subjects:
Antibodies
Apoptosis
AT-101
Breast cancer
Cancer therapies
Cell culture
Chromosomes
Cytotoxicity
Deoxyribonucleic acid
DNA
Drug dosages
Experiments
Immunotherapy
Laboratories
Monoclonal antibodies
Patients
PI3K/AKT
Proteins
Signal transduction
Software
synergism
Targeted cancer therapy
trastuzumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AT-101 is a polyphenolic compound with potent anti-apoptotic effects in various cancers. In this study, the possible synergistic cytotoxic and apoptotic effect of trastuzumab/AT-101 combination was investigated in HER2-positive breast cancer cell lines. SKBR-3, MDA-MB-453 and MCF-10A cell lines were treated with a trastuzumab/AT-101 combination. Synergistic cytotoxicity and apoptosis effects were shown and then PI3K and Akt protein levels were studied. The trastuzumab/AT-101 combination induced synergistic cytotoxicity and apoptosis in both breast cancer cells but not in MCF-10A cells. Combination treatment induced cytotoxicity via inhibiting PI3K/AKT but not the MAPK/ERK pathway. The trastuzumab/AT-101 combination may be a good candidate for patients with trastuzumab-resistant Her2-positive breast cancer and inhibition of the PI3K/AKT pathway may be one of the underlying mechanisms.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2019-0521